Developing New Ways to Detect Respiratory Impairment Early in ALS
Thomas Jefferson University · with National Institute of Neurological Disorders and Stroke (NINDS) · NCT07844590
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 70
- US sites recruiting
- 1
- Study start
- September 2026
- Record last updated
- September 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this observational study is to develop new ways to detect early changes associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The study will examine whether changes in breathing, magnetic resonance imaging (MRI) of the brainstem and spinal cord, and blood markers can identify early signs of ALS before major physical changes occur.
The main questions the study aims to answer are:
- Can changes in automatic breathing help identify early ALS-related changes?
- Can breathing measures distinguish people with ALS from people without ALS?
- Do people with genetic risk for ALS who show changes in breathing also have changes in the brainstem and spinal cord or higher levels of blood markers associated with nerve damage?
Participants will complete breathing and muscle function tests, an MRI scan of the brainstem and spinal cord, and blood testing. The study will include people with ALS, people with genetic risk for ALS who do not yet have symptoms, and healthy adults for comparison.
Conditions: Amyotrophic Lateral Sclerosis (ALS)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Symptomatic participants with ALS must have an ALS Functional Rating Scale-Revised (ALSFRS-R) score of 47/48 or less at the time of recruitment.
- Asymptomatic/presymptomatic participants must have a pathogenic C9orf72 expansion of at least 25 repeats or a similar genetic abnormality known to be associated with ALS.
- Healthy control participants must have no clinically identifiable neurological deficits based on medical history and screening. -
Exclusion Criteria
- Any safety concern or contraindication to MRI based on MRI safety screening.
- Healthy control participants who do not pass the neurological screening.
- Pregnancy.
- Metal implants above the waist, including cardiac pacemakers or brain, neck, cervical, or thoracic implants.
- Neurocognitive impairment.
- Inability or unwillingness to provide informed consent.
- Younger than 18 years of age.
Recruiting US locations
Thomas Jefferson University - Center City
Philadelphia, PA 19107
Site contact: Dana Johnson, DPT · 215-326-9153 · Dana.Johnson@jefferson.edu
Study contacts (from the official record)
- Jayakrishnan Nair, PhD, PT · 352-871-5888 · Jayakrishnan.Nair@jefferson.edu
- Dana Johnson, DPT · 215-326-9153 · dana.johnson@jefferson.edu
Similar studies in Pennsylvania
All neurology studies in Pennsylvania →- RecruitingPhase 1/Phase 2Overnight stay mentioned
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Vector Y Therapeutics
- Location
- Philadelphia, PA + 3 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
University of Pennsylvania
- Location
- Philadelphia, PA + 2 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingHealthy volunteersEarly Phase 1
Localizing Epileptic Networks Using MRI and iEEG
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
University of Pennsylvania
- Location
- Philadelphia, PA
- Eligibility basics
- Ages 40–80